Erste Group Bank Decreases Earnings Estimates for Pfizer

Pfizer Inc. (NYSE:PFE) – Stock analysts at Erste Group Bank dropped their FY2026 earnings estimates for Pfizer in a note issued to investors on Wednesday, July 15th. Erste Group Bank analyst H. Engel now expects that the biopharmaceutical company will post earnings of $2.92 per share for the year, down from their prior forecast of $2.95. The consensus estimate for Pfizer’s current full-year earnings is $2.96 per share.

Several other research analysts also recently weighed in on the company. Weiss Ratings upgraded Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, May 6th. Morgan Stanley upped their price objective on shares of Pfizer from $27.00 to $28.00 and gave the company an “equal weight” rating in a report on Friday, April 10th. Citigroup increased their target price on shares of Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 29th. HSBC downgraded shares of Pfizer from a “buy” rating to a “hold” rating and reduced their target price for the stock from $32.00 to $28.00 in a research note on Monday, July 6th. Finally, Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $28.50.

Pfizer Price Performance

Shares of NYSE PFE opened at $25.08 on Friday. The firm has a market cap of $142.94 billion, a price-to-earnings ratio of 19.15 and a beta of 0.35. The stock has a fifty day simple moving average of $25.21 and a two-hundred day simple moving average of $26.17. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. Pfizer has a 1-year low of $23.11 and a 1-year high of $28.75.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The firm had revenue of $14.45 billion during the quarter, compared to the consensus estimate of $13.84 billion. During the same period in the prior year, the firm earned $0.92 EPS. The company’s revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. Pfizer’s dividend payout ratio is 131.30%.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Cary Street Partners Financial LLC increased its position in shares of Pfizer by 10.2% during the second quarter. Cary Street Partners Financial LLC now owns 153,898 shares of the biopharmaceutical company’s stock valued at $3,706,000 after buying an additional 14,274 shares during the period. Rosenberg Matthew Hamilton boosted its position in shares of Pfizer by 214.3% in the second quarter. Rosenberg Matthew Hamilton now owns 2,722 shares of the biopharmaceutical company’s stock valued at $66,000 after acquiring an additional 1,856 shares during the period. Advocate Group LLC boosted its position in shares of Pfizer by 11.0% in the second quarter. Advocate Group LLC now owns 394,161 shares of the biopharmaceutical company’s stock valued at $9,491,000 after acquiring an additional 39,109 shares during the period. GRIMES & Co WEALTH MANAGEMENT LLC grew its stake in Pfizer by 1.2% during the second quarter. GRIMES & Co WEALTH MANAGEMENT LLC now owns 805,088 shares of the biopharmaceutical company’s stock valued at $19,387,000 after acquiring an additional 9,806 shares in the last quarter. Finally, Fort Washington Investment Advisors Inc. OH grew its stake in Pfizer by 1.0% during the second quarter. Fort Washington Investment Advisors Inc. OH now owns 2,061,791 shares of the biopharmaceutical company’s stock valued at $49,648,000 after acquiring an additional 19,752 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Recent commentary continues to focus on Pfizer’s pipeline potential, with articles asking whether the company can strengthen its growth story through new drug development and recent approvals, which could support a longer-term rebound. Can Pfizer (NYSE:PFE) Strengthen Its Pipeline Story?
• Positive Sentiment: Pfizer remains attractive to income-focused investors, with coverage highlighting it as a high-yield dividend stock and a potential “buy on the dip” name, which may help limit downside. 3 High-Yield Dividend Stocks to Buy and Hold
• Neutral Sentiment: Analysts are still modeling solid full-year earnings, but Erste Group slightly trimmed its FY2026 EPS estimate for Pfizer to $2.92 from $2.95, signaling only a small downward revision versus the consensus of $2.96.
• Neutral Sentiment: Another valuation-focused note said Pfizer looks “fairly priced” given mixed pipeline risks, suggesting the stock may not be obviously cheap despite its lower valuation and high dividend.
• Negative Sentiment: Pfizer suspended sales of Premarin vaginal cream in India because of supply challenges, adding another operational headwind for the company. Pfizer suspends sales of Premarin vaginal cream in India, citing supply challenges
• Negative Sentiment: Arbutus Biopharma filed international patent lawsuits against Pfizer and BioNTech over lipid nanoparticle technology used in mRNA vaccines, keeping legal risk and potential costs in focus for PFE. Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech…

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.